Tech Center 1600 • Art Units: 1635 1636 1674
This examiner grants 75% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19343405 | THERAPEUTIC CIRCULAR DNA FORMS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS VII, LLC |
| 18622413 | VON WILLEBRAND FACTOR (VWF)-TARGETING AGENTS AND METHODS OF USING THE SAME | Non-Final OA | Ohio State Innovation Foundation |
| 17622048 | NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS | Non-Final OA | Ohio State Innovation Foundation |
| 18171130 | USE OF A1CF INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION | Non-Final OA | Hoffmann-La Roche Inc. |
| 17443702 | Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 18340582 | GENETIC ELEMENTS DRIVING CIRCULAR RNA TRANSLATION AND METHODS OF USE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17905285 | METHOD FOR DIAGNOSIS AND/OR PROGNOSIS OF LIVER DISEASE PROGRESSION AND RISK OF HEPATOCELLULAR CARCINOMA AND DISCOVERY OF THERAPEUTIC COMPOUNDS AND TARGETS TO TREAT LIVER DISEASE AND CANCER | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 19085810 | INHIBITORS OF EXPRESSION AND/OR FUNCTION | Final Rejection | E-Therapeutics PLC |
| 17906444 | HETERONUCLEIC ACID CONTAINING MORPHOLINO NUCLEIC ACID | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 17602035 | Pharmaceutical Composition for Treating Muscle Disease | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY |
| 17160050 | TARGETING GENE AMPLIFICATION IN CANCER USING TRIPLEX FORMATION AS A THERAPEUTIC STRATEGY | Final Rejection | Yale University |
| 18009069 | USE OF MICRO-RNA TO IMPROVE AND TREAT CHRONIC PHASE CARDIAC FUNCTION | Non-Final OA | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM |
| 18485352 | COMPOSITIONS USEFUL FOR TREATING SPINAL AND BULBAR MUSCULAR ATROPHY (SBMA) | Non-Final OA | The Trustees of the University of Pennsylvania |
| 18415999 | Increasing Specificity for RNA-Guided Genome Editing | Final Rejection | The General Hospital Corporation |
| 18033009 | ENGINEERED Cas12f PROTEIN | Non-Final OA | THE UNIVERSITY OF TOKYO |
| 18316981 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION AND GEOGRAPHIC ATROPHY | Final Rejection | University of Virginia Patent Foundation |
| 18306680 | THERAPEUTIC TARGETING OF ACTIVATED AVIL-INDUCED SARCOMAS | Non-Final OA | University of Virginia Patent Foundation |
| 18248982 | NOVEL RNA COMPOSITIONS AND METHODS FOR INHIBITING ANGPTL3 | Non-Final OA | SANOFI |
| 17638339 | COMPOSITIONS AND METHODS FOR INHIBITING PCSK9 | Final Rejection | SANOFI |
| 18027293 | METHODS FOR TREATING NEUROLOGICAL DISEASE | Non-Final OA | ASKBIO INC. |
| 17616599 | EPH2A APTAMER AND USES THEREOF | Non-Final OA | UNIVERSITY OF IOWA RESEARCH FOUNDATION |
| 18547071 | OLIGONUCLEOTIDE FOR INDUCING N-EXON SKIPPING DURING REST MRNA PRECURSOR PROCESSING | Non-Final OA | Osaka University |
| 17792661 | INHIBITION OF TAP63 REGULATED ONCOGENIC LONG NON-CODING RNAS (TROLLS) IN THE TREATMENT OF CANCER | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18376217 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | Alnylam Pharmaceuticals, Inc. |
| 17945151 | COMPOSITIONS AND METHODS FOR TREATING SUBJECTS HAVING A HETEROZYGOUS ALANINE-GLYOXYLATE AMINOTRANSFERASE GENE (AGXT) VARIANT | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17794637 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | ALNYLAM PHARMACEUTICALS, INC. |
| 17683423 | XANTHINE DEHYDROGENASE (XDH) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17625545 | EXONS 45-55 SKIPPING USING MUTATION-TAILORED COCKTAILS OF ANTISENSE MORPHOLINOS IN THE DMD GENE | Non-Final OA | The Governors of the University of Alberta |
| 18016109 | METHODS AND COMPOSITIONS FOR CRISPR/CAS9 GUIDE RNA EFFICIENCY AND SPECIFICITY AGAINST GENETICALLY DIVERSE HIV-1 ISOLATES | Final Rejection | Trustees Of Dartmouth College |
| 17869611 | METHODS FOR LABELING AND TARGETING CELLS | Non-Final OA | Whitehead Institute for Biomedical Research |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy